Deborah A. Taira

Prof. Dr. Deborah A. Taira


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2012 in Preventing Chronic Disease
Verified
Journal Article
Open access
DTDeborah A. Taira
Deborah A. Taira
TSTetine Sentell
Tetine Sentell
STSheri Tokumaru
Sheri Tokumaru
RGRoy Goo
Roy Goo
JDJames W. Davis
James W. Davis
MMMarjorie M. Mau
Marjorie M. Mau
Although glycemic control is known to reduce complications associated with diabetes, it is an elusive goal for many patients with diabetes. The objective of this study was to identify factors associated with sustained poor glycemic control, some glycemic variability, and wide glycemic variability among diabetes patients over 3 years. This retrospective study was conducted among 2,970 diabetes patients with poor glycemic control (hemoglobin A1c [HbA1c] >9%) who were enrolled in a health plan in Hawaii in 2006. We conducted multivariable logistic regressions to examine factors related to sustained poor control, some glycemic variability, and wide glycemic variability during the next 3 years. Independent variables evaluated as possible predictors were age, sex, type of insurance coverage, morbidity, diabetes duration, history of cardiovascular disease, and number of medications. Longer duration of diabetes, being under age 35, and taking 15 or more medications were significantly associated with sustained poor glycemic control. Preferred provider organization and Medicare (vs health maintenance organization) enrollees and patients with high morbidity were less likely to have sustained poor glycemic control. Wide glycemic variability was significantly related to being younger than age 50, longer duration of diabetes, having coronary artery disease, and taking 5 to 9 medications per year. Results indicate that duration of diabetes, age, number of medications, morbidity, and type of insurance coverage are risk factors for sustained poor glycemic control. Patients with these characteristics may need additional therapies and targeted interventions to improve glycemic control. Patients younger than age 50 and those with a history of coronary heart disease should be warned of the health risks of wide glycemic variability.

1 August 2014 in Population Health Management
Verified
Journal Article
Closed access
DTDeborah A. Taira
Deborah A. Taira
CMCarolyn Ma
Carolyn Ma
AKAudrey Kumasaka
Audrey Kumasaka
RSReid Shimada
Reid Shimada
JDJames Davis
James Davis
The objectives of this study were to describe patient characteristics and types of medications taken by those with poor glycemic control (A1c>7%) despite being adherent to antidiabetic medications. This is a retrospective analysis of administrative data from adult patients with diabetes enrolled in a large health plan in Hawaii (n=21,267 observations for 11,013 individuals) and adherent to their antidiabetic medications. Multivariable logistic regressions were estimated to determine characteristics and types of medications associated with poor glycemic control. Separate models were estimated to examine category of medication (insulin only, 1 oral medication, multiple oral medications, both oral medications and insulin) and specific therapeutic class of oral antidiabetic medications. Despite being adherent to their medications, 56.1% of patients had poor glycemic control. Compared to patients taking combination sulfonylureas, patients had a higher odds of having A1c>7% for all other oral diabetic medications, with odds ratios ranging from OR=2.07 for sulfonylureas alone to OR=1.33 for combination DPP-4 inhibitors. More than half of patients in this study had poor A1c control despite being adherent to their medications. This suggests that physicians, pharmacists, and other providers may need to monitor treatment regimens more carefully, encourage healthy behaviors, and intensify pharmacological treatment as needed. ( Population Health Management 2014;17:218–223)

4 April 2013 in Journal of Pharmaceutical Health Services Research
Verified
Journal Article
Open access
PDF file
DTDeborah A. Taira
Deborah A. Taira
CTCandace Tan
Candace Tan
JDJames Davis
James Davis
MMMarjorie Mau
Marjorie Mau
Objective. To identify factors associated with years of medication adherence and to examine the relationship between years of adherence and healthcare u

26 July 2016 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
TSTetine Sentell
Tetine Sentell
TSTodd Seto
Todd Seto
MYMalia M. Young
Malia M. Young
MVMay Vawer
May Vawer
MQMichelle L. Quensell
Michelle L. Quensell
DTDeborah A. Taira
Deborah A. Taira
Potentially preventable hospitalizations (PPH) for heart failure (HF) and diabetes mellitus (DM) cost the United States over $14 billion annually. Studies about PPH typically lack patient perspectives, especially across diverse racial/ethnic groups with known PPH health disparities. English-speaking individuals with a HF or DM-related PPH (n = 90) at the largest hospital in Hawai‘i completed an in-person interview, including open-ended questions on precipitating factors to their PPH. Using the framework approach, two independent coders identified patient-reported factors and pathways to their PPH. Seventy-two percent of respondents were under 65 years, 30 % were female, 90 % had health insurance, and 66 % had previously been hospitalized for the same problem. Patients’ stories identified immediate, precipitating, and underlying reasons for the admission. Underlying background factors were critical to understanding why patients had the acute problems necessitating their hospitalizations. Six, non-exclusive, underlying factors included: extreme social vulnerability (e.g., homeless, poverty, no social support, reported by 54 % of respondents); health system interaction issues (e.g., poor communication with providers, 44 %); limited health-related knowledge (42 %); behavioral health issues (e.g., substance abuse, mental illness, 36 %); denial of illness (27 %); and practical problems (e.g., too busy, 6 %). From these findings, we developed a model to understand an individual’s pathways to a PPH through immediate, precipitating, and underlying factors, which could help identify potential intervention foci. We demonstrate the model’s utility using five examples. In a young, predominately insured population, factors well outside the traditional purview of the hospital, or even clinical medicine, critically influenced many PPH. Patient perspectives were vital to understanding this issue. Innovative partnerships and policies should address these issues, including linkages to social services and behavioral health.

1 October 2014 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
DTDeborah A. Taira
Deborah A. Taira
KDKendra Demaris
Kendra Demaris
RGRoy Goo
Roy Goo
CMChristina Mnatzaganian
Christina Mnatzaganian
HSHelen Wong Smith
Helen Wong Smith
The 2014 American Diabetes Association guidelines denote four means of diagnosing diabetes. The first of these is a glycosylated hemoglobin (HbA1c) >6.5%. This literature review summarizes studies (n=47) in the USA examining the significance, strengths, and limitations of using HbA1c as a diagnostic tool for diabetes, relative to other available means. Due to the relatively recent adoption of HbA1c as a diabetes mellitus diagnostic tool, a hybrid systematic, truncated review of the literature was implemented. Based on these studies, we conclude that HbA1c screening for diabetes has been found to be convenient and effective in diagnosing diabetes. HbA1c screening is particularly helpful in community-based and acute care settings where tests requiring fasting are not practical. Using HbA1c to diagnose diabetes also has some limitations. For instance, HbA1c testing may underestimate the prevalence of diabetes, particularly among whites. Because this bias differs by racial group, prevalence and resulting estimates of health disparities based on HbA1c screening differ from those based on other methods of diagnosis. In addition, existing evidence suggests that HbA1c screening may not be valid in certain subgroups, such as children, women with gestational diabetes, patients with human immunodeficiency virus, and those with prediabetes. Further guidelines are needed to clarify the appropriate use of HbA1c screening in these populations.

1 August 2012 in Journal Of Health Care For The Poor and Underserved
Verified
Journal Article
Closed access
PDF file
DTDeborah A. Taira
Deborah A. Taira
JDJames W. Davis
James W. Davis
SBS. Kalani Brady
S. Kalani Brady
RCRichard S. Chung
Richard S. Chung
Objective. To examine disparities in disease prevalence related to age and race/ethnicity. Study design. Retrospective observational study. Methods. Eligible population included enrollees with largest insurer in Hawai‘i. Chronic diseases were identified from claims data (1999–2009) based on algorithms including diagnostic codes and pharmaceutical utilization. Relative risk of heart disease and its risk factors were calculated for Native Hawaiians and Asian sub-groups by age. Results. Prevalence of heart disease and its risk factors differed substantially by age and race/ethnicity. Native Hawaiians and Filipinos had higher rates of hypertension and diabetes; Asians had highest rates of hyperlipidemia. Whites had the lowest prevalence of risk factors yet their risk of heart disease equaled other groups. Conclusion. Prevalence curves began diverging at age 30 for risk factors and age 40 for heart disease. This suggests approaches to reduce the burden of disease for vulnerable groups need to begin in early adulthood if not sooner.